-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

Benzinga·05/15/2026 11:37:28
Listen to the news
BTIG analyst Mark Massaro reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $2.5 price target.